QIAGEN launches syndromic test for QIAstat-Dx device to combat Monkeypox health emergency

QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms

SPARSH Hospital organises a walkathon to create awareness on organ donation

Donor privilege cards given to the families of all the donors from across Karnataka as a token of appreciation

ENHERTU delays disease progression in DESTINYBreast02 Phase 3 Trial

Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients

Vascular experts establish appropriate use of IVUS in peripheral interventions

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

Congenica announces partnership with Avesthagen

New deal strengthens Congenica’s presence in India

MoU signed between Ministry of Ayush and MeitY

MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years

We must be careful in adopting global technological practices, says Union Health Secretary

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces

Apollo Hospitals posts Q1 FY23 consolidated PAT at Rs. 317.11 Cr

Apollo Hospital Group completed the acquisition of a hospital asset in Gurugram for a consideration of around Rs 450 crore.